Volume 28, Number 1—January 2022
Synopsis
Extensively Drug-Resistant Carbapenemase-Producing Pseudomonas aeruginosa and Medical Tourism from the United States to Mexico, 2018–2019
, D. Cal Ham1, Gillian McAllister, Amanda R. Smith, Maureen Vowles, Kelly Kauber, Melba Zambrano, Gretchen Rodriguez, Kelley Garner, Kaitlyn Chorbi, P. Maureen Cassidy, Shannon McBee, Rhett J. Stoney, Kathleen Moser, Margarita E. Villarino, Oscar E. Zazueta, Amelia Bhatnagar, Erisa Sula, Richard A. Stanton, Allison C. Brown, Alison L. Halpin, Lauren Epstein, Maroya Spalding Walters, and for the Verona Integron-Encoded Metallo-β-Lactamase–Producing Carbapenem-Resistant Pseudomonas aeruginosa Medical Tourism Investigation Team2
Table 3
Susceptibility of 10 Verona integron-encoded, metallo-β-lactamase‒producing, carbapenem-resistant Pseudomonas aeruginosa isolates from US medical tourists traveling to Tijuana, Mexico, January 2018–December 2019*
| ID no. | MIC, μg/mL |
||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AMK | ATM | FEP | CAZ | CZA | C/T | CIP | CST | DOR | GEN | IPM | LVX | MEM | TZP | TOB | |
| 15 | 64 (R) | 16 (I) | 16 (I) | 32 (R) | >16/4 (R) | >16/4 (R) | >8 (R) | 1 (S) | >8 (R) | 4 (S) | >64 (R) | >8 (R) | >8 (R) | 32/4 (I) | >16 (R) |
| 14 | 16 (S) | 32 (R) | 32 (R) | 32 (R) | >16/4 (R) | >16/4 (R) | >8 (R) | 1 (S) | 4 (I) | 16 (R) | >64 (R) | >8 (R) | 8 (R) | 64/4 (I) | >16 (R) |
| 22 | 64 (R) | 16 (I) | 16 (I) | 32 (R) | >16/4 (R) | >16/4 (R) | >8 (R) | 1 (S) | >8 (R) | 4 (S) | >64 (R) | >8 (R) | >8 (R) | 64/4 (I) | >16 (R) |
| 1 | 64 (R) | 16 (I) | 16 (I) | 32 (R) | >16/4 (R) | >16/4 (R) | >8 (R) | 1 (S) | >8 (R) | 4 (S) | >64 (R) | >8 (R) | >8 (R) | 64/4 (I) | >16 (R) |
| 3 | 64 (R) | 16 (I) | 16 (I) | 32 (R) | >16/4 (R) | >16/4 (R) | >8 (R) | 2 (S) | >8 (R) | 2 (S) | >64 (R) | >8 (R) | >8 (R) | 64/4 (I) | >16 (R) |
| 5 | 64 (R) | 16 (I) | 16 (I) | 32 (R) | >16/4 (R) | >16/4 (R) | >8 (R) | 1 (S) | >8 (R) | 2 (S) | >64 (R) | >8 (R) | >8 (R) | 32/4 (I) | >16 (R) |
| 9 | 32 (I) | 16 (I) | 16 (I) | 32 (R) | >16/4 (R) | >16/4 (R) | >8 (R) | 2 (S) | >8 (R) | 2 (S) | >64 (R) | >8 (R) | >8 (R) | 32/4 (I) | >16 (R) |
| 8 | 32 (I) | 16 (I) | 16 (I) | 32 (R) | >16/4 (R) | >16/4 (R) | >8 (R) | 2 (S) | >8 (R) | 2 (S) | >64 (R) | >8 (R) | >8 (R) | 32/4 (I) | >16 (R) |
| 10 | 32 (I) | 16 (I) | 16 (I) | 32 (R) | >16/4 (R) | >16/4 (R) | >8 (R) | 2 (S) | >8 (R) | 2 (S) | >64 (R) | >8 (R) | >8 (R) | 32/4 (I) | >16 (R) |
| 13 | 32 (I) | 16 (I) | 16 (I) | 32 (R) | >16/4 (R) | >16/4 (R) | >8 (R) | 2 (S) | >8 (R) | 4 (S) | >64 (R) | >8 (R) | >8 (R) | 32/4 (I) | >16 (R) |
*Isolates were tested against 15 antimicrobial drugs by using reference broth microdilution. All isolates were ST111, except for 14 which was a unique ST. AMK, amikacin; ATM, aztreonam; C/T, ceftolozane/tazobactam; CAZ, ceftazidime; CIP, ciprofloxacin; CST, colistin; CZA, ceftazidime/avibactam; DOR, doripenem; FEP, cefepime; GEN, gentamicin; I, intermediate; ID, identification; IPM, imipenem; LVX, levofloxacin; MEM, meropenem; R, resistant; S, sensitive; ST, sequence; TOB, tobramycin; TZP, piperacillin/tazobactam.
1These authors contributed equally to this article.
2Members of this team are listed at the end of this article.